Profund Advisors LLC increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 79.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,783 shares of the company’s stock after purchasing an additional 22,983 shares during the period. Profund Advisors LLC owned 0.09% of Protagonist Therapeutics worth $1,430,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the stock. Teacher Retirement System of Texas raised its position in shares of Protagonist Therapeutics by 7.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 12,214 shares of the company’s stock worth $337,000 after purchasing an additional 847 shares during the last quarter. Legal & General Group Plc raised its position in shares of Protagonist Therapeutics by 8.4% during the 4th quarter. Legal & General Group Plc now owns 14,408 shares of the company’s stock worth $157,000 after purchasing an additional 1,118 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Protagonist Therapeutics by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 139,769 shares of the company’s stock worth $3,310,000 after acquiring an additional 1,275 shares during the period. Principal Financial Group Inc. grew its stake in Protagonist Therapeutics by 13.4% in the 4th quarter. Principal Financial Group Inc. now owns 11,738 shares of the company’s stock worth $128,000 after acquiring an additional 1,389 shares during the period. Finally, Ensign Peak Advisors Inc grew its stake in Protagonist Therapeutics by 14.9% in the 3rd quarter. Ensign Peak Advisors Inc now owns 12,270 shares of the company’s stock worth $103,000 after acquiring an additional 1,590 shares during the period. 98.63% of the stock is currently owned by institutional investors and hedge funds.
Protagonist Therapeutics Stock Up 2.6 %
Shares of NASDAQ PTGX opened at $17.24 on Tuesday. Protagonist Therapeutics, Inc. has a 52-week low of $7.24 and a 52-week high of $30.10. The firm has a fifty day moving average of $16.11 and a 200-day moving average of $20.63. The stock has a market capitalization of $994.37 million, a PE ratio of -6.58 and a beta of 1.85.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. StockNews.com cut shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. JMP Securities lifted their target price on shares of Protagonist Therapeutics from $35.00 to $37.00 and gave the stock a “market outperform” rating in a research note on Friday, November 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 10th. JPMorgan Chase & Co. lowered their price objective on shares of Protagonist Therapeutics from $36.00 to $34.00 and set an “overweight” rating for the company in a research note on Monday, September 25th. Finally, Capital One Financial assumed coverage on shares of Protagonist Therapeutics in a research note on Monday, October 30th. They set an “overweight” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $35.25.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.
- Five stocks we like better than Protagonist Therapeutics
- What Investors Need to Know to Beat the Market
- Safeguard your portfolio with these three bargain stocks
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- Membership clubs gain leverage for the consumer rebound
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.